PDL BioPharma CEO Presents at Goldman Sachs Healthcare Conference …Seeking AlphaIn looking for second generation products rituxan they basically divided the franchisee in half, half were targeted towards blood-borne cancers of rituximab being in that…
|
Idelalisib and rituximab produce responses in 97% with CLL
The Oncology Report CHICAGO – When paired with rituximab, the experimental agent idelalisib was associated with durable progression-free survival rates in older patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma, Dr. Susan M. O’Brien … |
Medgadget.comRadioactive Lead Coupled to Tumor-Seeking Antibodies to Kill CancerMedgadget.comradioactive antibodies Radioactive Lead Coupled to Tumor Seeking Antibodies to Kill Cancer The business of ferrying tumor killing particles and depositing them…
New Report on Monoclonal Antibodies Partnering Terms and Agreements …SBWire (press release)Albany, NY — (SBWIRE) — 06/11/2013 — The Monoclonal Antibodies Partnering Terms and Agreements report provides comprehensive understanding and unprecedented…
90Y-Epratuzumab Study Shows Improvement of Therapy Results Following R …PipelineReview.com (press release)VANCOUVER, Canada I June 10, 2013 I Immunomedics, Inc. (IMMU), a biopharmaceutical company primarily focused on the development of monoclonal an…
Bendamustine plus rituximab shows promise in relapsed, refractory DLBCLHealioThe combination of bendamustine and rituximab was effective and well tolerated as salvage therapy in patients with relapsed or refractory diffuse large B-cell lymphoma who und…
Immunomedics Announces Combo of 90Y-Epratuzumab-Veltuzumab is Active in …Benzinga1 Moreover, given that the anti-CD20 veltuzumab also compared well to published results with rituximab,^2,3 the Company is conducting a Phase I/II study to evaluate the …
Immunomedics (IMMU) Issues Encouraging Update for Epratuzumab w/ 90Y on …StreetInsider.com (subscription)Immunomedics, Inc. (Nasdaq: IMMU) reported that adding two doses of epratuzumab labeled with the radioisotope, yttrium-90 (90Y), to a combination…
|
Chronische Immun-Thrombozytopenie: Das Ansprechen erhöht sich bei Zugabe …
Deutsches Ärzteblatt Bei der primären Immun-Thrombozytopenie (ITP) werden Thrombozyten durch Vermittlung von Autoantikörpern abgebaut, und gleichzeitig ist ihre Neubildung gestört; klinisch resultieren daraus vor allem Blutungskomplikationen. Kortikosteroide gelten als … |
CTI Announces Data Presentations at the 18th Congress of the European …The Herald | HeraldOnline.comThe SmPC is available at www.pixuvri.eu. CTI is currently accruing patients into a Phase 3 trial comparing PIXUVRI and rituximab with gemcitabine and …